

Vivek K Asati

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9570474/publications.pdf>

Version: 2024-02-01

40
papers

2,028
citations

516710

16
h-index

289244

40
g-index

47
all docs

47
docs citations

47
times ranked

3319
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of novel ALK2 inhibitors of pyrazolo-pyrimidines: A computational study. Journal of Biomolecular Structure and Dynamics, 2022, 40, 10422-10436.	3.5	3
2	Discovery of Novel Antimalarial Drugs Based on Thiosemicarbazone Derivatives: An In Silico Approach. Current Signal Transduction Therapy, 2022, 17, 59-74.	0.5	0
3	In-silico studies for the development of novel RET inhibitors for cancer treatment. Journal of Molecular Structure, 2022, 1251, 132040.	3.6	8
4	Recent Advances in PI3 Kinase Inhibitors: Anticancer Activities and Structure-Activity Relationships. Mini-Reviews in Medicinal Chemistry, 2022, 22, 2146-2165.	2.4	5
5	An analytical review for the estimation of montelukast sodium. Separation Science Plus, 2022, 5, 120-137.	0.6	0
6	Integrated computational approach on sodium-glucose co-transporter 2 (SGLT2) Inhibitors for the development of novel antidiabetic agents. Journal of Molecular Structure, 2021, 1227, 129511.	3.6	18
7	The Recent Development of Piperazine and Piperidine Derivatives as Antipsychotic Agents. Mini-Reviews in Medicinal Chemistry, 2021, 21, 362-379.	2.4	10
8	Current Insights into the Chemistry and Antitubercular Potential of Benzimidazole and Imidazole Derivatives. Mini-Reviews in Medicinal Chemistry, 2021, 21, 643-657.	2.4	16
9	Structural Aspects of mTOR Inhibitors: In Progress to Search Potential Compounds. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, .	1.7	2
10	Pyrazolopyrimidines as anticancer agents: A review on structural and target-based approaches. European Journal of Medicinal Chemistry, 2021, 225, 113781.	5.5	23
11	A Computational approach to discover potential quinazoline derivatives against CDK4/6 kinase. Journal of Molecular Structure, 2021, 1245, 131079.	3.6	6
12	An exhaustive perspective on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent. European Journal of Medicinal Chemistry, 2020, 204, 112523.	5.5	25
13	Structural prediction of novel pyrazolo-pyrimidine derivatives against PIM-1 kinase: In-silico drug design studies. Journal of Molecular Structure, 2020, 1217, 128375.	3.6	7
14	Perspectives of medicinally privileged chalcone based metal coordination compounds for biomedical applications. European Journal of Medicinal Chemistry, 2019, 174, 142-158.	5.5	71
15	An updated patent review of therapeutic applications of chalcone derivatives (2014-present). Expert Opinion on Therapeutic Patents, 2019, 29, 385-406.	5.0	38
16	PIM kinase inhibitors: Structural and pharmacological perspectives. European Journal of Medicinal Chemistry, 2019, 172, 95-108.	5.5	49
17	Anti-Inflammatory activity of seeds extract of datura stramonium against carrageenan induced paw edema on albino wistar rats. Journal of Pharmaceutical and Biological Sciences, 2019, 7, 41-46.	0.4	4
18	3D-QSAR and Molecular Docking Studies on Oxadiazole Substituted Benzimidazole Derivatives: Validation of Experimental Inhibitory Potencies Towards COX-2. Current Computer-Aided Drug Design, 2019, 15, 277-293.	1.2	2

#	ARTICLE	IF	CITATIONS
19	Formulation and evaluation of sustain released matrix tablet of atenolol. <i>Journal of Drug Delivery and Therapeutics</i> , 2019, 9, 183-189.	0.5	4
20	Recent Perspectives Of Chalcone-Based Molecules As Protein Tyrosine Phosphatase 1b (Ptp1b) Inhibitors. , 2019, , 235-251.		3
21	Virtual Screening, Molecular Docking, and DFT Studies of Some Thiazolidine-2,4-diones as Potential PIM-1 Kinase Inhibitors. <i>ChemistrySelect</i> , 2018, 3, 127-135.	1.5	18
22	Design, synthesis and molecular modeling studies of novel thiazolidine-2,4-dione derivatives as potential anti-cancer agents. <i>Journal of Molecular Structure</i> , 2018, 1154, 406-417.	3.6	30
23	MEK inhibitors in oncology: a patent review (2015-Present). <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 887-906.	5.0	34
24	3D-QSAR and virtual screening studies of thiazolidine-2,4-dione analogs: Validation of experimental inhibitory potencies towards PIM-1 kinase. <i>Journal of Molecular Structure</i> , 2017, 1133, 278-293.	3.6	13
25	K-Ras and its inhibitors towards personalized cancer treatment: Pharmacological and structural perspectives. <i>European Journal of Medicinal Chemistry</i> , 2017, 125, 299-314.	5.5	39
26	Chalcone Derivatives: Anti-inflammatory Potential and Molecular Targets Perspectives. <i>Current Topics in Medicinal Chemistry</i> , 2017, 17, 3146-3169.	2.1	108
27	Nature Inspired Green Fabrication Technology for Silver Nanoparticles. <i>Current Nanomedicine</i> , 2017, 7, 5-24.	0.6	6
28	SWFB and GA Strategies for Variable Selection in QSAR Studies for the Validation of Thiazolidine-2,4-Dione Derivatives as Promising Antitumor Candidates. <i>Indian Journal of Pharmaceutical Education and Research</i> , 2017, 51, 436-451.	0.6	4
29	QSAR studies for some thiazolidine-2,4-dione derivatives as PIM-2 kinase inhibitors. <i>Medicinal Chemistry Research</i> , 2016, 25, 1329-1339.	2.4	3
30	PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives. <i>European Journal of Medicinal Chemistry</i> , 2016, 109, 314-341.	5.5	452
31	Molecular modeling studies of some thiazolidine-2,4-dione derivatives as 15-PGDH inhibitors. <i>Medicinal Chemistry Research</i> , 2016, 25, 94-108.	2.4	9
32	Triggering PIK3CA Mutations in PI3K/Akt/mTOR Axis: Exploration of Newer Inhibitors and Rational Preventive Strategies. <i>Current Pharmaceutical Design</i> , 2016, 22, 6039-6054.	1.9	14
33	Mutant B-Raf Kinase Inhibitors as Anticancer Agents. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2016, 16, 1558-1575.	1.7	13
34	Chalcones and their therapeutic targets for the management of diabetes: Structural and pharmacological perspectives. <i>European Journal of Medicinal Chemistry</i> , 2015, 92, 839-865.	5.5	188
35	Chalcone scaffolds as anti-infective agents: Structural and molecular target perspectives. <i>European Journal of Medicinal Chemistry</i> , 2015, 101, 496-524.	5.5	147
36	Anti-cancer chalcones: Structural and molecular target perspectives. <i>European Journal of Medicinal Chemistry</i> , 2015, 98, 69-114.	5.5	382

#	ARTICLE	IF	CITATIONS
37	1,3,4-Oxadiazoles: An emerging scaffold to target growth factors, enzymes and kinases as anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2015, 97, 124-141.	5.5	142
38	Synthesis, characterization and antimicrobial evaluation of some 1,3-benzothiazole-2-yl-hydrazone derivatives. <i>Arabian Journal of Chemistry</i> , 2015, 8, 495-499.	4.9	10
39	Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents. <i>European Journal of Medicinal Chemistry</i> , 2014, 87, 814-833.	5.5	110
40	RECENT THERAPEUTIC PROGRESS OF CHALCONE SCAFFOLD BEARING COMPOUNDS AS PROSPECTIVE ANTI-GOUT CANDIDATES. <i>Journal of Critical Reviews</i> , 0, , 1-5.	0.1	5